Examining the Role of Microbiota-Centered Interventions in Cancer Therapeutics: Applications for Urothelial Carcinoma
Modern advances in genomic and molecular technologies have sparked substantial research on the human intestinal microbiome over the past decade. A deeper understanding of the microbiome has illuminated that dysbiosis, or a disruption in the microbiome, is associated with inflammatory disease states...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-03-01
|
| Series: | Technology in Cancer Research & Treatment |
| Online Access: | https://doi.org/10.1177/15330338231164196 |
| _version_ | 1797855324731867136 |
|---|---|
| author | Jake C. Drobner BA Benjamin J. Lichtbroun MD Eric A. Singer MD, MA, MS, FACS, FASCO Saum Ghodoussipour MD |
| author_facet | Jake C. Drobner BA Benjamin J. Lichtbroun MD Eric A. Singer MD, MA, MS, FACS, FASCO Saum Ghodoussipour MD |
| author_sort | Jake C. Drobner BA |
| collection | DOAJ |
| description | Modern advances in genomic and molecular technologies have sparked substantial research on the human intestinal microbiome over the past decade. A deeper understanding of the microbiome has illuminated that dysbiosis, or a disruption in the microbiome, is associated with inflammatory disease states and carcinogenesis. Novel therapies that target the microbiome and restore healthy flora may have value in dampening the immunopathologic state induced by dysbiosis. A narrative review of the literature on the use of microbiota-centered interventions (MCIs) was conducted. Several randomized clinical trials show that MCIs can augment response to immune checkpoint inhibitor (ICI) therapy in patients with metastatic cancer. Clinical trials have also demonstrated that modulation of the intestinal microbiome can enhance recovery and reduce infectious complications in the surgical management of colorectal adenocarcinoma. Overall, these major discoveries suggest future clinical applications of MCIs for a wide range of immune-mediated conditions. These results may also translate to improved patient outcomes in systemic immunotherapy for urothelial carcinoma as well as in patients recovering from radical cystectomy (RC), which is complicated by high infection rates. Further research is needed to evaluate the optimal bacterial composition of microbiota-centered therapies and the specific cellular changes that lead to improved tumor antigen recognition after microbiota-centered therapies. |
| first_indexed | 2024-04-09T20:21:56Z |
| format | Article |
| id | doaj.art-4d69bd99639a4b8c84ba74d6474e2380 |
| institution | Directory Open Access Journal |
| issn | 1533-0338 |
| language | English |
| last_indexed | 2024-04-09T20:21:56Z |
| publishDate | 2023-03-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Technology in Cancer Research & Treatment |
| spelling | doaj.art-4d69bd99639a4b8c84ba74d6474e23802023-03-30T23:33:39ZengSAGE PublishingTechnology in Cancer Research & Treatment1533-03382023-03-012210.1177/15330338231164196Examining the Role of Microbiota-Centered Interventions in Cancer Therapeutics: Applications for Urothelial CarcinomaJake C. Drobner BA0Benjamin J. Lichtbroun MD1Eric A. Singer MD, MA, MS, FACS, FASCO2Saum Ghodoussipour MD3 Division of Urologic Oncology, and , New Brunswick, NJ, USA Division of Urologic Oncology, and , New Brunswick, NJ, USA Division of Urologic Oncology, , Columbus, OH, USA Division of Urologic Oncology, and , New Brunswick, NJ, USAModern advances in genomic and molecular technologies have sparked substantial research on the human intestinal microbiome over the past decade. A deeper understanding of the microbiome has illuminated that dysbiosis, or a disruption in the microbiome, is associated with inflammatory disease states and carcinogenesis. Novel therapies that target the microbiome and restore healthy flora may have value in dampening the immunopathologic state induced by dysbiosis. A narrative review of the literature on the use of microbiota-centered interventions (MCIs) was conducted. Several randomized clinical trials show that MCIs can augment response to immune checkpoint inhibitor (ICI) therapy in patients with metastatic cancer. Clinical trials have also demonstrated that modulation of the intestinal microbiome can enhance recovery and reduce infectious complications in the surgical management of colorectal adenocarcinoma. Overall, these major discoveries suggest future clinical applications of MCIs for a wide range of immune-mediated conditions. These results may also translate to improved patient outcomes in systemic immunotherapy for urothelial carcinoma as well as in patients recovering from radical cystectomy (RC), which is complicated by high infection rates. Further research is needed to evaluate the optimal bacterial composition of microbiota-centered therapies and the specific cellular changes that lead to improved tumor antigen recognition after microbiota-centered therapies.https://doi.org/10.1177/15330338231164196 |
| spellingShingle | Jake C. Drobner BA Benjamin J. Lichtbroun MD Eric A. Singer MD, MA, MS, FACS, FASCO Saum Ghodoussipour MD Examining the Role of Microbiota-Centered Interventions in Cancer Therapeutics: Applications for Urothelial Carcinoma Technology in Cancer Research & Treatment |
| title | Examining the Role of Microbiota-Centered Interventions in Cancer Therapeutics: Applications for Urothelial Carcinoma |
| title_full | Examining the Role of Microbiota-Centered Interventions in Cancer Therapeutics: Applications for Urothelial Carcinoma |
| title_fullStr | Examining the Role of Microbiota-Centered Interventions in Cancer Therapeutics: Applications for Urothelial Carcinoma |
| title_full_unstemmed | Examining the Role of Microbiota-Centered Interventions in Cancer Therapeutics: Applications for Urothelial Carcinoma |
| title_short | Examining the Role of Microbiota-Centered Interventions in Cancer Therapeutics: Applications for Urothelial Carcinoma |
| title_sort | examining the role of microbiota centered interventions in cancer therapeutics applications for urothelial carcinoma |
| url | https://doi.org/10.1177/15330338231164196 |
| work_keys_str_mv | AT jakecdrobnerba examiningtheroleofmicrobiotacenteredinterventionsincancertherapeuticsapplicationsforurothelialcarcinoma AT benjaminjlichtbrounmd examiningtheroleofmicrobiotacenteredinterventionsincancertherapeuticsapplicationsforurothelialcarcinoma AT ericasingermdmamsfacsfasco examiningtheroleofmicrobiotacenteredinterventionsincancertherapeuticsapplicationsforurothelialcarcinoma AT saumghodoussipourmd examiningtheroleofmicrobiotacenteredinterventionsincancertherapeuticsapplicationsforurothelialcarcinoma |